Posted by Michael Wonder on 11 Nov 2022
Dupixent (dupilumab) recommended for EU approval by the CHMP for the treatment of prurigo nodularis
11 November 2022 - Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis.
The EMA’s CHMP has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union to treat adults with moderate to severe prurigo nodularis who are candidates for systemic therapy.
